{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:51:54Z","timestamp":1770994314664,"version":"3.50.1"},"reference-count":32,"publisher":"Akademiai Kiado Zrt.","issue":"1","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["EuJMI"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:p>Nowadays, multidrug-resistant bacteria are considered as an increasing serious threat to public health worldwide. Global and local surveillance data are helpful in the application of the most efficient antimicrobial agent in bacterial infections. In the current study, we aimed to analyze the activity of the previously cleared agent ceftolozane\/tazobactam (C\/T) in African and European multidrug-resistant Gram-negative bacteria. Susceptibility testing was performed on 147 extended-spectrum \u03b2-lactamase (107 <jats:italic>Escherichia coli<\/jats:italic> and 40 <jats:italic>Klebsiella pneumoniae<\/jats:italic>) and 103 carbapenemase-producing Gram-negative bacteria using Etest according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints. Among the extended-spectrum \u03b2-lactamase producing isolates, 91 <jats:italic>Escherichia coli<\/jats:italic> isolates (85%) and 23 <jats:italic>Klebsiella pneumoniae isolates<\/jats:italic> (57.5%) were susceptible towards C\/T whereas out of the 103 carbapenemase-producing isolates 102 (99.0%) were C\/T-resistant. C\/T should be included in susceptibility testing to fairly administer this antimicrobial agent in infections caused by multidrug-resistant bacteria. It may be considered as a therapy option for infections caused by extended-spectrum \u03b2-lactamase-producing bacteria once susceptibility to this antimicrobial combination has been confirmed.<\/jats:p>","DOI":"10.1556\/1886.2019.00001","type":"journal-article","created":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T13:28:48Z","timestamp":1549632528000},"page":"1-4","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":12,"title":["Ceftolozane\/tazobactam susceptibility testing in extended-spectrum betalactamase- and carbapenemase-producing gram-negative bacteria of various clonal lineages"],"prefix":"10.1556","volume":"9","author":[{"given":"Carlo","family":"Pazzini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parviz","family":"Ahmad-Nejad","sequence":"additional","affiliation":[{"name":"Faculty of Health, Center for Clinical and Translational Research, Institute of Medical Laboratory Diagnostics, HELIOS University Clinic Wuppertal, Witten\/Herdecke University, Witten, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beniam","family":"Ghebremedhin","sequence":"additional","affiliation":[{"name":"Faculty of Health, Center for Clinical and Translational Research, Institute of Medical Laboratory Diagnostics, HELIOS University Clinic Wuppertal, Witten\/Herdecke University, Witten, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"rf1","series-title":"J Hosp Infect","article-title":"Prevention and control of multi-drug-resistant Gram-negative bacteria: recommendations from a Joint Working Party","author":"Wilson\n              AP","year":"2016","unstructured":"Wilson\n              AP\n            , LivermoreDM, OtterJA, WarrenRE, JenksP, EnochDA, et al., Prevention and control of multi-drug-resistant Gram-negative bacteria: recommendations from a Joint Working Party. J Hosp Infect. 2016;92:S1\u201344.26598314"},{"key":"rf2","series-title":"Dtsch Med Wochenschr","first-page":"2657","article-title":"Extended-spectrum of beta-lactamases (ESBL): yesterday ESBL: and today ESBL, carbapenemase-producing and multiresistant bacteria","volume":"137","author":"Ghebremedhin\n              B","year":"2012","unstructured":"Ghebremedhin\n              B\n            \n          . Extended-spectrum of beta-lactamases (ESBL): yesterday ESBL: and today ESBL, carbapenemase-producing and multiresistant bacteria. Dtsch Med Wochenschr. 2012;137:2657\u201362.23225190"},{"key":"rf3","series-title":"Biomed Res Int","first-page":"2475067","article-title":"Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens","volume":"2016","author":"Santajit\n              S","year":"2016","unstructured":"Santajit\n              S\n            , IndrawattanaN. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. Biomed Res Int. 2016;2016:2475067.27274985"},{"key":"rf4","series-title":"Lancet","first-page":"1949","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner\n              FM","year":"2015","unstructured":"Wagenlehner\n              FM\n            , UmehO, SteenbergenJ, YuanG, DarouicheRO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385:1949\u201356.25931244"},{"key":"rf5","series-title":"Clin Infect Dis","first-page":"1462","article-title":"Ceftolozane\/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)","volume":"60","author":"Solomkin\n              J","year":"2015","unstructured":"Solomkin\n              J\n            , HershbergerE, MillerB, PopejoyM, FriedlandI, SteenbergenJ, et al., Ceftolozane\/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). Clin Infect Dis. 2015;60:1462\u201371."},{"key":"rf6","series-title":"Clinical","author":"US National Institute of Health","unstructured":"US National Institute of Health\n            \n          , ClinicalTrials.gov."},{"key":"rf7","series-title":"Clin Infect Dis","first-page":"853","article-title":"Ceftolozane\/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa","volume":"61","author":"Gelfand\n              MS","year":"2015","unstructured":"Gelfand\n              MS\n            , ClevelandKO. Ceftolozane\/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa. Clin Infect Dis. 2015;61:853\u20135.26021991"},{"key":"rf8","series-title":"J Clin Microbiol","first-page":"4049","article-title":"In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum beta-lactamases","volume":"52","author":"Estabrook\n              M","year":"2014","unstructured":"Estabrook\n              M\n            , BussellB, ClugstonSL, BushK. In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum beta-lactamases. J Clin Microbiol. 2014;52:4049\u201352.25143578"},{"key":"rf9","series-title":"Antimicrob Agents Chemother","first-page":"4521","article-title":"In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-beta-Lactamase-Harboring Enterobacteriaceae","volume":"59","author":"Melchers\n              MJ","year":"2015","unstructured":"Melchers\n              MJ\n            , MilACvan, MoutonJW. In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-beta-Lactamase-Harboring Enterobacteriaceae, Antimicrob Agents Chemother. 2015;59:4521\u201325.25987635"},{"key":"rf10","series-title":"J Antimicrob Chemother","first-page":"2713","article-title":"Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12)","volume":"69","author":"Sader\n              HS","year":"2014","unstructured":"Sader\n              HS\n            , FarrellDJ, CastanheiraM, FlammRK, JonesRN. Antimicrobial activity of ceftolozane\/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). J Antimicrob Chemother. 2014;69:2713\u201322.24917579"},{"key":"rf11","series-title":"Int J Antimicrob Agents","first-page":"502","article-title":"In vitro activity of ceftolozane\/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study","volume":"46","author":"Tato\n              M","year":"2015","unstructured":"Tato\n              M\n            , Garcia-CastilloM, BofarullAM, CantonR, Group CS. In vitro activity of ceftolozane\/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study. Int J Antimicrob Agents. 2015;46:502\u201310.26315199"},{"key":"rf12","series-title":"Clin Ther","first-page":"1564","article-title":"Susceptibility Profile of Ceftolozane\/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals","volume":"37","author":"Sutherland\n              CA","year":"2015","unstructured":"Sutherland\n              CA\n            , NicolauDP. Susceptibility Profile of Ceftolozane\/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals. Clin Ther. 2015;37:1564\u201371.26088525"},{"key":"rf13","series-title":"Antimicrob Agents Chemother","first-page":"3091","article-title":"Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot\n              G","year":"2014","unstructured":"Cabot\n              G\n            , BruchmannS, MuletX, ZamoranoL, MoyaB, JuanC, et al., Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother. 2014;58:3091\u201399.24637685"},{"key":"rf14","series-title":"Infect Dis Ther","first-page":"73","article-title":"Successful Treatment of Multi-Drug Resistant Pseudomonas aeruginosa Bacteremia with the Recommended Renally Adjusted Ceftolozane\/Tazobactam Regimen","volume":"5","author":"Patel\n              UC","year":"2016","unstructured":"Patel\n              UC\n            , NicolauDP, SabzwariRK. Successful Treatment of Multi-Drug Resistant Pseudomonas aeruginosa Bacteremia with the Recommended Renally Adjusted Ceftolozane\/Tazobactam Regimen. Infect Dis Ther. 2016;5:73\u20139.26935574"},{"key":"rf15","series-title":"Case Rep Infect Dis","first-page":"1628932","article-title":"Treatment of Polymicrobial Osteomyelitis with Ceftolozane-Tazobactam: Case Report and Sensitivity Testing of Isolates","volume":"2016","author":"Jolliff\n              JC","year":"2016","unstructured":"Jolliff\n              JC\n            , HoJ, JosonJ, HeidariA, JohnsonR. Treatment of Polymicrobial Osteomyelitis with Ceftolozane-Tazobactam: Case Report and Sensitivity Testing of Isolates. Case Rep Infect Dis. 2016;2016:1628932.27437155"},{"key":"rf16","series-title":"Clin Microbiol Infect","first-page":"E49","article-title":"Sequence type ST131 and ST10 complex (ST617) predominant among CTX-M-15-producing Escherichia coli isolates from Nigeria","volume":"18","author":"Aibinu\n              I","year":"2012","unstructured":"Aibinu\n              I\n            , OdugbemiT, KoenigW, GhebremedhinB. Sequence type ST131 and ST10 complex (ST617) predominant among CTX-M-15-producing Escherichia coli isolates from Nigeria. Clin Microbiol Infect. 2012;18:E49\u201351.22192452"},{"key":"rf17","series-title":"Breakpoint tables for interpretation of in vitro susceptiblity testing","author":"EUCAST","year":"2018","unstructured":"EUCAST\n            \n          . Breakpoint tables for interpretation of in vitro susceptiblity testing. EUCAST; 2018."},{"key":"rf18","series-title":"Clin Infect Dis","first-page":"1256","article-title":"Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans","volume":"57","author":"Colpan\n              A","year":"2013","unstructured":"Colpan\n              A\n            , JohnstonB, PorterS, ClabotsC, AnwayR, ThaoL. et al., Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin Infect Dis. 2013;57:1256\u201365.23926176"},{"key":"rf19","series-title":"J Antimicrob Chemother","first-page":"1981","article-title":"Measuring trends of outpatient antibiotic use in Europe: jointly modelling longitudinal data in defined daily doses and packages","volume":"69","author":"Bruyndonckx\n              R","year":"2014","unstructured":"Bruyndonckx\n              R\n            , HensN, AertsM, GoossensH, MolenberghsG, CoenenS. Measuring trends of outpatient antibiotic use in Europe: jointly modelling longitudinal data in defined daily doses and packages. J Antimicrob Chemother. 2014;69:1981\u20136.24623832"},{"key":"rf20","series-title":"Int J Antimicrob Agents","first-page":"533","article-title":"Ceftolozane\/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)","volume":"43","author":"Farrell\n              DJ","year":"2014","unstructured":"Farrell\n              DJ\n            , SaderHS, FlammRK, JonesRN. Ceftolozane\/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents. 2014;43:533\u20139\u201d.24856078"},{"key":"rf21","series-title":"Clin Infect Dis","first-page":"1549","article-title":"Dissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia","volume":"41","author":"Peleg\n              AY","year":"2005","unstructured":"Peleg\n              AY\n            , FranklinC, BellJM, SpelmanDW. Dissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia. Clin Infect Dis. 2005;41:1549\u201356."},{"key":"rf22","series-title":"Clin Infect Dis","first-page":"1557","article-title":"Acquired metallo-beta-lactamases: an increasing clinical threat","volume":"41","author":"Rossolini\n              GM","year":"2005","unstructured":"Rossolini\n              GM\n            \n          . Acquired metallo-beta-lactamases: an increasing clinical threat. Clin Infect Dis. 2005;41:1557\u201358.16267726"},{"key":"rf23","series-title":"Pharmacotherapy","first-page":"701","article-title":"Ceftolozane\/Tazobactam: A Novel Cephalosporin\/beta-Lactamase Inhibitor Combination","volume":"35","author":"Cho\n              JC","year":"2015","unstructured":"Cho\n              JC\n            , FiorenzaMA, EstradaSJ. Ceftolozane\/Tazobactam: A Novel Cephalosporin\/beta-Lactamase Inhibitor Combination. Pharmacotherapy. 2015;35:701\u201315.26133315"},{"key":"rf24","series-title":"Antimicrob Agents Chemother","first-page":"7358","article-title":"Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean countries and detection of two novel beta-lactamases, GES-22 and VIM-35","volume":"58","author":"Castanheira\n              M","year":"2014","unstructured":"Castanheira\n              M\n            , CostelloSE, WoosleyLN, DeshpandeLM, DaviesTA, JonesRN. Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean countries and detection of two novel beta-lactamases, GES-22 and VIM-35. Antimicrob Agents Chemother. 2014;58:7358\u201366.25267671"},{"key":"rf25","series-title":"J Hosp Med","first-page":"559","article-title":"Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009","volume":"8","author":"Zilberberg\n              MD","year":"2013","unstructured":"Zilberberg\n              MD\n            , ShorrAF. Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009. J Hosp Med. 2013;8:559\u201363.24022878"},{"key":"rf26","series-title":"Int J Antimicrob Agents","first-page":"224","article-title":"Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010","volume":"41","author":"Hawser\n              SP","year":"2013","unstructured":"Hawser\n              SP\n            , BadalRE, BouchillonSK, HobanDJ, BiedenbachDJ, CantonR. et al., Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010. Int J Antimicrob Agents. 2013;41:224\u20138.23305657"},{"key":"rf27","series-title":"Int J Antimicrob Agents","article-title":"Emerging carbapenemases: a global perspective","author":"Walsh\n              TR","year":"2010","unstructured":"Walsh\n              TR\n            \n          . Emerging carbapenemases: a global perspective. Int J Antimicrob Agents. 2010;36:S8\u201314.21129630"},{"key":"rf28","series-title":"Clin Microbiol Rev","first-page":"306","article-title":"Metallo-beta-lactamases: the quiet before the storm?","volume":"18","author":"Walsh\n              TR","year":"2005","unstructured":"Walsh\n              TR\n            , TolemanMA, PoirelL, NordmannP. Metallo-beta-lactamases: the quiet before the storm?. Clin Microbiol Rev. 2005;18:306\u201325.15831827"},{"key":"rf29","series-title":"J Med Microbiol","first-page":"1317","article-title":"Carbapenem-resistance mechanisms of multidrug-resistant Pseudomonas aeruginosa","volume":"62","author":"Fuste\n              E","year":"2013","unstructured":"Fuste\n              E\n            , Lopez-JimenezL, SeguraC, GainzaE, VinuesaT, VinasM. Carbapenem-resistance mechanisms of multidrug-resistant Pseudomonas aeruginosa. J Med Microbiol. 2013;62:1317\u201325.23722434"},{"key":"rf30","series-title":"J Clin Microbiol","first-page":"533","article-title":"Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria","volume":"29","author":"Baker\n              CN","year":"1991","unstructured":"Baker\n              CN\n            , StockerSA, CulverDH, ThornsberryC. Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microbiol. 1991;29:533\u20138."},{"key":"rf31","series-title":"Microb Drug Resist","first-page":"412","article-title":"Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options","volume":"22","author":"Cerceo\n              E","year":"2016","unstructured":"Cerceo\n              E\n            , DeitelzweigSB, ShermanBM, AminAN. Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options. Microb Drug Resist. 2016;22:412\u201331.26866778"},{"key":"rf32","series-title":"Int. J. Antimicrob. Agents","first-page":"250","article-title":"New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance","volume":"47","author":"Syue\n              LS","year":"2016","unstructured":"Syue\n              LS\n            , ChenYH, KoWC, HsuehPR. New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance. Int. J. Antimicrob. Agents. 2016;47:250\u20138.27005457"}],"container-title":["European Journal of Microbiology and Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.akademiai.com\/doi\/full-xml\/10.1556\/1886.2019.00001","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/view\/journals\/1886\/9\/1\/article-p1.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/1886\/9\/1\/article-p1.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/1886\/9\/1\/article-p1.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T16:37:43Z","timestamp":1704299863000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/1886\/9\/1\/article-p1.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":32,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1556\/1886.2019.00001","relation":{},"ISSN":["2062-8633"],"issn-type":[{"value":"2062-8633","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}